El SRAA y el SARS-CoV-2: el acertijo a resolver

The first case of COVID-19 was reported on 31 December 2019 in Wuhan, China. Ever since there has been unprecedented and growing interest in learning about all aspects of this new disease. Debate has been generated as to the association between antihypertensive therapy with renin-angiotensin-aldoste...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, M., Aiello, E.A., Ennis, I.L., Villa-Abrille, M.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SEH-LELHA. Published by Elsevier España, S.L.U. 2020
Materias:
Artículo Especial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250776/
https://www.ncbi.nlm.nih.gov/pubmed/32527699
http://dx.doi.org/10.1016/j.hipert.2020.05.005
Descripción
Sumario:The first case of COVID-19 was reported on 31 December 2019 in Wuhan, China. Ever since there has been unprecedented and growing interest in learning about all aspects of this new disease. Debate has been generated as to the association between antihypertensive therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors and SARS-CoV-2 infection. While many questions as yet remain unanswered, the aim of this report is to inform health professionals about the current state of knowledge. Because this is an ever-evolving topic, the recommendation is that it be updated as new evidence becomes available. Below, we provide a review of pre-clinical and clinical studies that link coronavirus to the RAAS.

Ejemplares similares